Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of MK-2870 vs physician's choice in 3L+ advanced/metastatic gastroesophageal adenocarcinoma
jRCT2031240133Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall survival. Started Jul 2024; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2031240133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240133.